DIASTAT ACUDIAL (diazepam) by Bausch + Lomb. Approved for benzodiazepine [epc]. First approved in 1997.
Drug data last refreshed 41m ago · AI intelligence enriched 1mo ago
DIASTAT ACUDIAL is a rectal gel formulation of diazepam, a benzodiazepine used for acute seizure management and anxiety disorders. The product delivers rapid CNS depression through GABA receptor agonism via the rectal route, bypassing oral administration challenges in acute settings. This formulation enables non-invasive delivery during seizure episodes or acute anxiety crises.
Product is approaching loss of exclusivity with modest Medicare spending ($23K in 2023) and minimal claim volume, signaling reduced team investment and focus on transition planning rather than growth initiatives.
Benzodiazepine
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Study to Assess the Time to Onset of Action of Staccato Alprazolam Versus Midazolam and Diazepam in Healthy Participants
Safety and Tolerability Study of Diazepam Buccal Film (DBF) in Subjects With Epilepsy
Treatment Of Alcohol Withdrawal Syndrome: Dexmedetomidine Vs Diazepam In A Hospital O'horán
Pharmacokinetics and Safety Study of Diazepam Buccal Film (DBF) in Pediatric Subjects With Epilepsy
A Study of Diazepam After Intranasal and Intravenous Administration to Healthy Volunteers
Worked on DIASTAT ACUDIAL at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on DIASTAT ACUDIAL offers limited career growth due to zero linked job openings and its LOE-approaching status, making it a non-strategic portfolio asset at Bausch + Lomb. Roles on this product focus on managed decline, generic transition planning, and maintaining relationships with remaining prescribers rather than field expansion or innovation.